20 December 2023
20 December 2023
The life sciences sector is set to see a significant amount of change in 2024.
argenx will not pursue further development of efgartigimod in pemphigus, instead, it will focus on ongoing severe autoimmune indications.
TransCon hGH, which is sold as Skytrofa, was first approved by the US Food and Drug Administration (FDA) in 2021 as a treatment for paediatric growth hormone deficiency (GHD).
The topline data announcement comes on the same day as Lilly further extends its tender offer for the acquisition of POINT.
The pivotal trial for Ablative’s Peregrine system met its primary endpoint in patients with uncontrolled hypertension.
The trial, comparing Sight Sciences’s TearCare device to Restasis, will now join the two cohorts ahead of crossover results expected by the end of 2024.
The company has announced the expansion into New South Wales, marking the third clinical trial site in its portfolio.
The selected dose of 180mg per cycle showed to have a better safety profile and efficacy in the trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
